Home News Reslizumab Continually Reduces Emergent Asthma Care at 1 Year back to News
minute read
A new subgroup analysis showed patients with severe, eosinophilic asthma administered reslizumab (Cinqair) over 12 months had meaningful improvement in outcomes including pulmonary function and disease-related healthcare resource use.
Topics: Press Coverage
13001 East 17th Place
Aurora, CO 80045
303.724.5375
© 2024 The Regents of the University of Colorado, a body corporate. All rights reserved.
Accredited by the Higher Learning Commission. All trademarks are registered property of the University. Used by permission only.
